Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers (HPTN066)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01276600
Recruitment Status : Completed
First Posted : January 13, 2011
Last Update Posted : November 30, 2011
Information provided by (Responsible Party):
HIV Prevention Trials Network

January 12, 2011
January 13, 2011
November 30, 2011
January 2011
October 2011   (Final data collection date for primary outcome measure)
  • Assess dose-proportionality [ Time Frame: 49 days ]
    Assess dose-proportionality of intracellular TFV-DP and FTC-TP from weekly to daily dosing (Arms 1-4).
  • Comparison of intra-individual variability--days 28 and 35 [ Time Frame: Days 28 and 35 ]
    Describe intra-individual variability in intracellular TFV-DP and FTC-TP concentrations at steady-state (comparison of Day 28 and Day 35).
Same as current
Complete list of historical versions of study NCT01276600 on Archive Site
  • Determine relationship between pre-dose and decaying concentrations [ Time Frame: Days 35 and 49 ]
    Describe the relationship between pre-dose and decaying concentrations of TFV, FTC, and their phosphorylated derivatives (TFV-DP and FTC-TP) in blood serum, peripheral blood mononuclear cells (PBMCs), CD4+ blood cells, total tissue cells, CD4+ tissue cells, tissue homogenate, semen, and luminal fluid at steady-state (Day 35 [pre-dose] and Day 49 [decaying, greater than one half-life for TFV-DP]).
  • Determine differences between men and women [ Time Frame: 49 days ]
    Describe differences in intracellular TFV-DP and FTC-TP steady-state between men and women.
  • Safety profiles [ Time Frame: 49 days ]
    Characterize the safety profiles of four different TDF/FTC PrEP regimens
Same as current
Not Provided
Not Provided
Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers
Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers
Describe the dose-proportionality and intra-individual variability of tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) at steady-state in healthy human participants taking Truvada® (FTC 200mg/TDF 300 mg) under direct observation.
This PK study is designed to establish the dose-proportionality of TFV and FTC (serum and intracellular forms) with daily to weekly dosing. This information is essential to (1) employ drug concentration as an adherence measure in future PrEP studies, and (2) to estimate the anticipated concentration of parent and active moieties of TFV and FTC in intermittent PrEP regimens associated with full adherence to a prescribed regimen. In addition, intra-individual variability will be assessed to improve sample size estimates in future PrEP studies that use drug concentration as an adherence measure or where PK-PD correlations are planned. The dose-proportionality of intra-cellular phosphates of the two components of the study product has not previously been established. Given the complexity of movement of these drugs between body compartments (central compartment, vaginal mucosal tissue, vaginal lumen, gastrointestinal mucosal tissue, gastrointestinal lumen), into cells within these compartments, and intra-cellular phosphorylation, it is possible that non-dose proportional kinetics, such as mixed or zero-order saturable processes may be operating.
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Drug: Emtricitabine/tenofovir
200mg of emtricitabine 300mg of tenofovir
  • Experimental: Arm 1
    1 tablet orally weekly
    Intervention: Drug: Emtricitabine/tenofovir
  • Experimental: Arm 2
    One tablet orally twice weekly
    Intervention: Drug: Emtricitabine/tenofovir
  • Experimental: Arm 3
    Two tablets orally twice weekly
    Intervention: Drug: Emtricitabine/tenofovir
  • Experimental: Arm 4
    One tablet orally daily
    Intervention: Drug: Emtricitabine/tenofovir
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
October 2011
October 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Participants who meet all of the following criteria are eligible for inclusion in this study:

  • 18 to 44 years of age, inclusive on the date of screening.
  • Provides informed consent for the study.
  • Non-reactive HIV rapid test results at the screening and enrollment visits.
  • An estimated calculated creatinine clearance (eCcr) at least 70 mL/min by the Cockcroft-Gault formula where:

    • eCcr (female) in mL/min = [(140 - age in years) x (weight in kg) x 0.85] / (72 x serum creatinine in mg/dL).
    • eCcr (male) in mL/min = [(140 - age in years) x (weight in kg)] / (72 x serum creatinine in mg/dL).
  • Participants are sexually active, defined as at least one sex (vaginal or anal intercourse) act in the 30 days prior to screening.
  • Participants must agree to use condoms for all coital events during study participation.
  • Intensive sampling cohort only:

    • Not using spermicide as a means of birth control (in conjunction with a condom or diaphragm)
  • Women must:

    • Be pre-menopausal
    • Have regular menstrual cycles with at least 21 days between menses (unless on contraception that causes amenorrhea or irregular menses)
    • Have a negative urine pregnancy test at screening and enrollment
    • Be utilizing an alternative method of birth control in addition to condoms (hormonal contraceptive, diaphragm or have undergone surgical sterilization) or have a vasectomized exclusive male partner.
    • Intensive sampling cohort only:

      • Have a cervix
      • Have documentation of a normal Pap smear within 12 months

Exclusion Criteria:

  • At screening::

    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 1.5 X the site laboratory ULN (upper limit of normal)
    • Hemoglobin less than 10.0 g/dL
    • Platelet count less than 100,000/mm3
    • Serum phosphate level below site laboratory LLN (lower limit of normal)
    • INR or aPTT greater than site laboratory ULN
    • Other safety tests (bicarbonate (HCO3), potassium (K), chloride (Cl), sodium (Na), calcium (Ca), fasting glucose) with results outside of the laboratories reference range
    • 1+ or greater protein on urine dipstick testing
    • 1+ or greater glucose on urine dipstick testing
  • Culture-confirmed urinary tract infection
  • Co-enrollment in any other HIV interventional research study (excluding behavioral only interventions) or prior enrollment in the active arm of a HIV vaccine trial.
  • Clinically apparent or patient report of active skin disorders including: rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, and pustular rash.
  • Women who are pregnant or breastfeeding.
  • One or more reactive HIV rapid test results at screening or enrollment, even if HIV infection is not confirmed.
  • Positive hepatitis B surface antigen (HBsAg) test.
  • Excessive use of alcohol (more than 4 drinks a day on a regular basis).
  • Interleukin therapy; medications with significant nephrotoxic potential, including but not limited to amphotericin B, aminoglycosides, cidofovir, foscarnet and systemic chemotherapy; and medications that may inhibit or compete for elimination via active renal tubular secretion (including but not limited to probenecid).
  • Participants with a history of having a gastrectomy, colostomy, ileostomy, or any other procedure altering the gastrointestinal tract or drug absorption.
  • Intensive sampling cohort only:

    • A positive test for syphilis, gonorrhea, or Chlamydia
    • A positive test for HSV-2 (individuals with active lesions only)
    • Findings consistent with bacterial vaginosis, vaginal candidiasis, or trichomonas (women only)
    • History of STI within 3 months prior to enrollment
    • Medications that prolong clotting time (e.g., warfarin, heparin, clopidogrel classes.)
    • Abnormalities of the colorectal mucosa, or significant colorectal symptom(s), which in the opinion of the clinician represents a contraindication to biopsy (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, and presence of symptomatic external hemorrhoids).
    • Clinically apparent pelvic exam finding (observed by study staff) of genital lesions, erythema, edema or any other abnormal physical or pelvic exam finding that, in the opinion of the investigator or designee, would contraindicate study participation.
    • Women who have had cervical procedures (conization, LEEP procedure, cryosurgery) within the previous 6 months.
    • Spermicide as a method for contraception within last 30 days
  • Any other reason or condition that in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Sexes Eligible for Study: All
18 Years to 44 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
HPTN 066
Not Provided
Not Provided
HIV Prevention Trials Network
HIV Prevention Trials Network
Not Provided
Study Chair: Craig Hendrix, MD Johns Hopkins University
Study Chair: Kristine Patterson, MD University of North Carolina
Study Chair: Kenneth Mayer, MD Brown University
Principal Investigator: Adriana Andrade, MD, MPH Johns Hopkins University
HIV Prevention Trials Network
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP